Search Result

Results for "

Benzamide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) ADC Linker (1) Amino Acid Derivatives (1) Apoptosis (2) Autophagy (1) Caspase (1) Cholinesterase (ChE) (2) COX (2) CXCR (2) Dopamine Receptor (8) Endogenous Metabolite (3) Fluorescent Dye (1) Fungal (1) GCGR (2) HDAC (6) iGluR (2) Isotope-Labeled Compounds (3) JAK (1) mAChR (1) Neuropeptide Y Receptor (2) Nucleoside Antimetabolite/Analog (2) PARP (3) Phosphatase (1) Phosphodiesterase (PDE) (1) PKD (1) PROTACs (6) Sirtuin (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (15)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Z0283

*Benzamide* Benzenecarboxamide; Phenylamide	Endogenous Metabolite PARP	Others
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-Z0283S

Benzamide-15N Benzenecarboxamide-¹⁵N; Phenylamide-¹⁵N	Endogenous Metabolite PARP	Others
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-B1224

Exalamide

2-(Hexyloxy)Benzamide
Fungal Infection

Exalamide (2-(Hexyloxy)benzamide), an arenecarboxamide, is a potent antifungal agent .

Exalamide 2-(Hexyloxy)Benzamide	Fungal	Infection
Exalamide (2-(Hexyloxy)benzamide), an arenecarboxamide, is a potent antifungal agent .

HY-U00415

Benzamide Derivative 1	Dopamine Receptor mAChR	Neurological Disease
Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.

HY-147256

Cavutilide

Others Cardiovascular Disease

Cavutilide, benzamide, is used as an antiarrhythmic, antiarythmique .

Cavutilide	Others	Cardiovascular Disease
Cavutilide, benzamide, is used as an antiarrhythmic, antiarythmique .

HY-145488

*MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D*	ADC Linker	Cancer
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W128037

*(S)-N-(1-Amino-5-guanidino-1-oxopentan-2-yl)benzamide* hydrochloride**	Amino Acid Derivatives	Others
(S)-N-(1-Amino-5-guanidino-1-oxopentan-2-yl)benzamide hydrochloride is an arginine derivative .

HY-B1883S

*3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3*	Isotope-Labeled Compounds	Others
3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d₃ is the deuterium labeled 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide[1]. 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134753

Teriflunomide impurity 3 4-Amino-N-(4-trifluoromethylphenyl)Benzamide	COX	Inflammation/Immunology
Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective COX-1 inhibitor with an IC₅₀ of 30 µM. Teriflunomide impurity 3 is less active against COX-2 (IC₅₀>100 µM) .

HY-Q49697

Sirtuin modulator 3

Sirtuin Metabolic Disease Inflammation/Immunology Cancer

Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a sirtuin modulator .

Sirtuin modulator 3	Sirtuin	Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a sirtuin modulator .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-U00020

AU-224

Others Metabolic Disease

AU-224 is a benzamide derivative used as a promising gastrointestinal prokinetic agent without significant side effects.

AU-224	Others	Metabolic Disease
AU-224 is a benzamide derivative used as a promising gastrointestinal prokinetic agent without significant side effects.

HY-B1059

Levosulpiride RV-12309; S-(-)-Sulpiride	Dopamine Receptor	Neurological Disease
Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class.

HY-12505

CX546 2 Publications Verification	iGluR Autophagy	Neurological Disease
CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects .

HY-100963

U-54494A

U-54494A is a benzamide derivative related to κ-opioid receptor agonists, U-54494A has an anticonvulsant activity .
HY-112731

TFAP

N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)Benzamide
COX Endogenous Metabolite Metabolic Disease

TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC₅₀ of 0.8 μM.

U-54494A
U-54494A is a benzamide derivative related to κ-opioid receptor agonists, U-54494A has an anticonvulsant activity .

TFAP N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)Benzamide	COX Endogenous Metabolite	Metabolic Disease
TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC₅₀ of 0.8 μM.

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-B0068

Azasetron hydrochloride 2 Publications Verification Y-25130 hydrochloride	5-HT Receptor	Neurological Disease
Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective 5-HT3 receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV) .

HY-B1059S

Levosulpiride-d3 RV-12309-d₃; S-(-)-Sulpiride-d₃	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Levosulpiride-d₃ is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].

HY-B0732S

Itopride-d6 hydrochloride HSR803-d₆ hydrochloride	Isotope-Labeled Compounds Cholinesterase (ChE) Dopamine Receptor	Neurological Disease
Itopride-d₆ (hydrochloride) is deuterium labeled Itopride (hydrochloride). Itopride hydrochloride (HSR803), a gastroprokinetic Benzamide (HY-Z0283) derivative, is an inhibitor of acetylcholinesterase (AChE) and dopamine D2 receptor[1][2].

HY-B1019

Sulpiride 5 Publications Verification	Dopamine Receptor	Neurological Disease
Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer .

HY-103414

Raclopride 1 Publications Verification	Dopamine Receptor	Neurological Disease
Raclopride is a dopamine D₂/D₃ receptor antagonist with potential antipsychotic effects. Raclopride binds to D₂ and D₃ receptors with K_is of 1.8 nM and 3.5 nM, respectively .

HY-108976

Raclopride tartrate	Dopamine Receptor	Neurological Disease
Raclopride tartrate is a selective dopamine D₂/D₃ receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D₂ and D₃ receptors with K_is of 1.8 nM and 3.5 nM, respectively .

HY-151370

AChE-IN-26	Cholinesterase (ChE)	Neurological Disease
AChE-IN-26 (compound 4a) is an AChE (acetylcholinesterase) inhibitor with an IC₅₀ value of 0.42 μM. AChE-IN-26 can be used for the research of Alzheimer’s disease .

HY-155597

h-NTPDase8-IN-1	Phosphatase	Metabolic Disease Inflammation/Immunology Cancer
h-NTPDase8-IN-1 (compound 2d) is a sulfamoyl-benzamides based and selective inhibitor for h-NTPDases8 (IC₅₀=0.28 μM). h-NTPDases8 is involved in a variety of physiological and pathological functions，such as thrombosis，diabetes，inflammation，and cancer .

HY-112547

CRT5 CRT0066051	PKD	Others
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-B1019R

Sulpiride (Standard)	Dopamine Receptor	Neurological Disease
Sulpiride (Standard) is the analytical standard of Sulpiride. This product is intended for research and analytical applications. Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer .

HY-145815

JPS014	HDAC PROTACs	Cancer
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145816

JPS016	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145818

JPS035	HDAC PROTACs	Cancer
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145819

JPS036	HDAC PROTACs	Cancer
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145816A

JPS016 TFA	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-145815A

JPS014 TFA	PROTACs HDAC Apoptosis	Cancer
JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 TFA degrades class I histone deacetylase (HDAC). JPS014 TFA is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-155355

LY836	iGluR	Neurological Disease
LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .

HY-W357200

N6-Benzoyl-7’-OH-N-trityl morpholino adenine N-[9-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-9H-purin-6-yl]-Benzamide	Nucleoside Antimetabolite/Analog	Cancer
N6-Benzoyl-7’-OH-N-trityl morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W357201

N4-Benzoyl-7’-OH-N-trityl morpholino cytosine N-[1-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-Benzamide	Nucleoside Antimetabolite/Analog	Cancer
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-146123

ATX inhibitor 20

Phosphodiesterase (PDE) Cancer

ATX inhibitor 20 (compound 24) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.3 nM .

ATX inhibitor 20	Phosphodiesterase (PDE)	Cancer
ATX inhibitor 20 (compound 24) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.3 nM .

Cat. No.	Product Name	Target	Research Area

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-W128037

*(S)-N-(1-Amino-5-guanidino-1-oxopentan-2-yl)benzamide* hydrochloride**	Amino Acid Derivatives	Others
(S)-N-(1-Amino-5-guanidino-1-oxopentan-2-yl)benzamide hydrochloride is an arginine derivative .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P4757

N1-Glutathionyl-spermidine disulfide

Peptides Others

N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
HY-P10026

Nisotirostide

LY-3457263
Peptides Metabolic Disease

Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P10016

Pegmolesatide HS-20039; EPO-018B	Peptides	Endocrinology
Pegmolesatide(HS-20039; EPO-018B) a synthetic peptide-based erythropoiesis-stimulating agent, can be used for ??the study of anemia in chronic kidney disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Z0283

*Benzamide* Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-112731

TFAP N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)Benzamide	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	COX Endogenous Metabolite
TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC₅₀ of 0.8 μM.

Cat. No.	Product Name	Chemical Structure

HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-B1059S

Levosulpiride-d3
Levosulpiride-d₃ is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].

HY-B1883S

*3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3*
3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d₃ is the deuterium labeled 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide[1]. 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0732S

Itopride-d6 hydrochloride
Itopride-d₆ (hydrochloride) is deuterium labeled Itopride (hydrochloride). Itopride hydrochloride (HSR803), a gastroprokinetic Benzamide (HY-Z0283) derivative, is an inhibitor of acetylcholinesterase (AChE) and dopamine D2 receptor[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Benzamide

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products